Journals / Experimental Biomedical Research / 2020 / Cilt: 3 - Sayı: 3

Investigation of therapeutic effect of Saccharomyces boulardii and translocation in immunosuppressed rats infected with Shigella sonnei

Pages
141–148
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: The administration of S. boulardii showed promising results for the therapy of S. sonnei infection in immunosuppressed rats, but therapeutic usage of S. boulardii should be carefully assessed by taking into consideration the risk it poses versus potential benefits in risk groups.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: To investigate the therapeutic effects of Saccharomyces boulardii (S. boulardii) and detect blood and tissue penetrations of S. boulardii and Shigella sonnei (S. sonnei) in immunosuppressed rats infected with S. sonnei.
📊
Key Findings & Data:Methods: Forty rats were divided into four groups: Group A (immunosuppressed, not-treated); Group B (immunosuppressed, treated with S. boulardii); Group C (immunosuppressed, infected with S. sonnei, treated with S. boulardii); Group D (immunosuppressed, infected with S. sonnei).
💡
Conclusion & Impact:Conclusion: The administration of S. boulardii showed promising results for the therapy of S. sonnei infection in immunosuppressed rats, but therapeutic usage of S. boulardii should be carefully assessed by taking into consideration the risk it poses versus potential benefits in risk groups.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Aim: To investigate the therapeutic effects of Saccharomyces boulardii (S. boulardii) and detect blood and tissue penetrations of S. boulardii and Shigella sonnei (S. sonnei) in immunosuppressed rats infected with S. sonnei. Methods: Forty rats were divided into four groups: Group A (immunosuppressed, not-treated); Group B (immunosuppressed, treated with S. boulardii); Group C (immunosuppressed, infected with S. sonnei, treated with S. boulardii); Group D (immunosuppressed, infected with S. sonnei). After taking samples for blood cultures, the rats were sacrificed. The large bowel, liver, spleen and mesenteric lymph nodes (MLN) were removed for microbiological examination. Results: S. boulardii in group B and S. sonnei in group D were isolated from blood in some rats. Statistical analysis of our data, showed that the numbers of translocated colonies in the liver and spleen were relatively higher for S. boulardii in Group B and for S. sonnei in Group D, without reaching levels of statistical significance. For MLN, colony counts in Group B was higher than Group C and A showing statistical significance. Conclusion: The administration of S. boulardii showed promising results for the therapy of S. sonnei infection in immunosuppressed rats, but therapeutic usage of S. boulardii should be carefully assessed by taking into consideration the risk it poses versus potential benefits in risk groups.

🔖

Cite This Article

BEHÇET, M., KAYA, A. D. (2020). Investigation of therapeutic effect of Saccharomyces boulardii and translocation in immunosuppressed rats infected with Shigella sonnei. Experimental Biomedical Research, Cilt: 3 - Sayı: 3, 141–148. https://ajindex.com/articles/157967

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Kotloff KL, Riddle MS, Platts-Mills JA, et al. Shigellosis. Lancet. 2018
  2. 391(10122):801-12. [2]Peirano G, Souza FS, Rodrigues DP. Shigella Study Group. Frequency of serovars and antimicrobial resistance in Shigella spp. from Brazil. Mem Inst Oswald Cruz. 2006
  3. 101(3):245-50. [3]Saınt-Marc T, Blehaut H, Musıal C, et al. AIDS-related diarrhea: a double-blind trial of Saccharomyces boulardii. Sem Hop Paris. 1995
  4. 71(23):735-41. [4]Rene K, Vidal PKE, Christine FM, et al. Shigella dysenteriae type-1 induced diarrhea in rats. Jpn J Infect Dis. 2005
  5. 58(6):335-37. [5]Güngör S, Kurultay N, Şener AG, et al. Demonstration of bacterial translocation in an experimental obstructive jaundice model in rats. Klimik Derg. 2003
  6. 16(3):121-25. [6]Sharif MR, Kashani HH, Ardakani AT, et al. The effect of a yeast probiotic on acute diarrhea in children. Probiotics Antimicrob Proteins. 2016
  7. 8(4):211-14. [7]Guarino A, Guandalini S, Lo Vecchio A. Probiotics for prevention and treatment of diarrhea. J Clin Gastroenterol. 2015
  8. 49(1):37-45. [8]Plein K, Hotz J. Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn's disease with special respect to chronic diarrhea a pilot study. Z Gastroenterol. 1993
  9. 31(2):129-34. [9]Castaneda Guillot C, Garcia Bacallao E, Santa Cruz Dominguez M, et al. Effects of Saccharomyces boulardii in children with chronic diarrhea, especially cases of giardiasis. Rev Mex Puericultura Pediatria 1995
  10. Feng JR, Wang F, Qiu X, et al. Efficacy and safety of probiotic-supplemented triple therapy for eradication of Helicobacter pylori in children: a systematic review and network meta-analysis. Eur J Clin Pharmacol. 2017
  11. 73(10):1199-208. [11]Czerucka D, Rampal P. Experimental effects of Saccharomyces boulardii on diarrheal Pathogens. Microbes Infect. 2002
  12. 4(7):733- 39. [12]Valdés-Varela L, Gueimonde M, RuasMadiedo P. Probiotics for prevention and treatment of Clostridium difficile infection. In: Mastrantonio P, Rupnik M. (eds) Updates on Clostridium difficile in Europe. Advances in Experimental Medicine and Biology, Springer, Cham 2018.vol 1050. p. 161-76. [13]Allen SJ. The potential of probiotics to prevent Clostridium difficile infection. Infect Dis Clin North Am. 2015
  13. 29(1):135- 44. [14]Rodrigues ACP, Nardi RM, Bambirra EA, et al. Effect of Saccharomyces boulardii against experimental oral infection with Salmonella typhimurium and Shigella flexeneri in conventional and gnotobiotic mice. J Appl Bacte